Company
Arix Bioscience PLC
LON:ARIX
Arix Bioscience is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. The company collaborates with exceptional entrepreneurs and provide the capital, expertise and global networks needed to help accelerate their ideas into important new treatments for patients. As a listed company, it aims to bring this growth phase of the industry to a broader range of investors.
180 stories · page 1 of 9
Arix Bioscience updates on clinical progress of four portfolio companies
Imara, Harpoon, Autolus and LogicBio have all released news recently
Arix Bioscience concludes strategic review, reshuffles board
The biotech-focused venture capital firm said it has completed stakeholder engagement and “now has a clear understanding of shareholder views”, which it said will enable it to implement its strategy more effectively
Arix Bioscience looks to boost the cutting edge of biotech
Arix invests in disruptive growth companies with the potential to significantly increase in worth as they progress through clinical trials and conduct financing rounds at higher valuations
Arix Bioscience's portfolio firm Amplyx snapped up by Pfizer
Amplyx, which develops therapies for debilitating and life-threatening diseases that affect people with compromised immune systems, will be acquired by Pfizer following an initial investment from the pharma giant in 2019
Arix Bioscience investee LogicBio signs strategic collaboration with CANBridge Pharma
SUNRISE is initially enrolling pediatric patients aged from 3 -12 years old, added the statement.
Arix portfolio firm Artios Pharma to collaborate with Novartis on cancer therapy development
The company said Artois will receive an upfront payment of US$20mln as part of the collaboration and will also be eligible to receive up to US$1.3bn in milestone payments as well as any sales royalties
Arix Bioscience leads US$152mln funding round for Pyxis Oncology
Arix will have a 5.6% ownership stake following the funding round
Arix Bioscience appoints biopharma veteran as venture partner
Dittmar has over 20 years of experience in the biotechnology sector with direct operating experience in the US, Europe and the Middle East
Arix Bioscience launches strategy review
"We believe it is necessary to accelerate the development of our capabilities to ensure we make the most of the opportunities before us," said chairman Naseem Amin
Archive
Proactive news headlines: Arix Bioscience, Powerhouse Energy, EQTEC, Samarkand Group...
A glance at some of the day's highlights from the Proactive Investors newswire
Proactive news headlines: Arix Bioscience, Gfinity, Eco (Atlantic) Oil & Gas, Union Jack Oil…
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Bioscience responds to open letter from Acacia Research Corp
The firm said it was “disappointed” that Acacia had decided to publish the letter on the same date as delivering it to the company, adding that it has “an experienced board that is committed to acting in the best interest of all shareholder
Arix Bioscience sees sharp uplift in net asset value in 2020
The highlight of the year was receiving £158mln from the sale of its stake in VelosBio, giving the venture capital firm plenty of firepower for more investments
Arix Bioscience brings in new non-executive directors
Both James Noble and Axel Wieandt will be joining the board effective from April 1
Arix Bioscience says portfolio company Autolus seeks US$100mln IPO
The biopharma is placing 14mln American depositary shares at US$7 each
Arix Bioscience says its managing director to depart for new post
Naseem Amin, Arix’s executive chairman, said Jonathan Tobin leaves with the company's very best wishes
Arix Bioscience portfolio firms Autolus and Imara issue updates
Nasdaq-listed Autolus said it is prioritising its AUTO1 treatment for Adult Acute Lymphoblastic Leukemia, with full data from its AUTO1-AL1 study expected in 2022
Archive
Small Cap Wrap - TruFin, Eagle Eye Solutions Group, Tungsten Corp and more...
HSS Hire Group,HSS.L transfer from Main to Aim. Mkt Cap c. £70m. Recently raised £52.6m. Leading supplier of tool and equipment for hire in the United Kingdom and Ireland and has provided equipment hire services in the United Kingdom for mo
Arix Bioscience portfolio company Atox Bio announces FDA acceptance of its NDA for ‘flesh-eating’ disorder treatment
The date set by the FDA for a decision is September 30, 2021